**Attachment 8: Statistical Power for Sample Size of the Central and Eastern European Renal Cancer Study**

Power calculations to determine the impact of VHL gene status, other etiologic and genetic risk factors on 5-year survival of RCC.

Table 8. Calculations for 80% power, two-sided test with alpha=0.05.

|  |  |
| --- | --- |
| 658 Living at 5-years; 439 Dead at 5-years | Minimal HR |
| VHL status: yes (93%)/no (7%) | 2.2 |
| Methylation (11%) vs no methylation | 1.8 |
| Any VHL mutation (82%) vs no mutation | 1.6 |
| Smoking (53% ever) | 1.5 |
| BMI (29%: <25, 44%: 25-30, 27%: 30plus) | 1.3 (fitted with trend) |
| Hypertension (yes 45%) | 1.5 |
| Gender (female: 40%) | 1.45 |
| Minor allele frequency=10% | 1.8 |
| Minor allele frequency=20% | 1.6 |
| Minor allele frequency=30% | 1.5 |